CHE

BEARISH

$421.11 Live

Chemed Corporation · NYSE

Target $443.0 (+5.2%)

$365.21 52W Range $583.96

CHE Chemed Corporation - Fundamental Analysis

BEARISH

Console Chart News

CHE Stock | Fundamental Analysis & Investment Insights

NYSE • Healthcare • Medical Care Facilities

Current Price Live

$421.11

Analyst Target

$443.0

+5.2% Upside

52W High

$583.96

52W Low

$365.21

Overview AI Snowflake Price Valuation Profitability Growth Health Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 25, 2026

Market cap

$5.65B

P/E

22.99

ROE

25.3%

Profit margin

10.5%

Debt/Equity

0.15

Dividend yield

0.6%

AI Analysis

AI-powered fundamental assessment

Confidence

85%

Chemed Corporation exhibits a stark divergence between its fundamental valuation and current market price, trading at a massive premium to its Graham Number ($171.6) and Intrinsic Value ($128.24). While the company maintains a stable Piotroski F-Score of 4/9 and an exceptionally low Debt/Equity ratio of 0.15, these health metrics are offset by negative YoY revenue and earnings growth. The combination of declining profitability, bearish insider activity from the CEO, and a valuation that is nearly 2.5x its defensive fair value suggests significant downside risk.

Key Strengths

Very low leverage with a Debt/Equity ratio of 0.15

Strong profitability metrics with ROE at 25.28% and ROA at 13.40%

Healthy operating margins of 16.62%

Sustainable dividend payout ratio of 12%

Positive analyst sentiment with a 'buy' recommendation

Key Risks

Severe overvaluation relative to Graham and Intrinsic value models

Negative growth trajectory (YoY Earnings Growth: -9.10%)

Bearish insider sentiment with multiple CEO sell transactions

Poor recent earnings track record (only 1 beat in last 4 quarters)

Tight liquidity indicated by a Quick Ratio of 0.90

AI Fair Value Estimate

Based on comprehensive analysis

$171.6

-59.3% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Overvalued with Declining Growth

Key drivers: Valuation Gap, Negative Earnings Growth, Insider Selling

Confidence

90%

Value

15/100

Ref P/E, PEG, Graham Number

Positives

Forward P/E (15.75) is lower than trailing P/E

Watchpoints

Price ($421.11) is significantly higher than Graham Number ($171.6)
Price is >3x Intrinsic Value ($128.24)
High Price/Book ratio of 5.90

Future

20/100

Ref Growth rates

Positives

Analyst target price ($443) is slightly above current price

Watchpoints

Negative YoY Revenue Growth (-0.10%)
Negative YoY Earnings Growth (-9.10%)
Negative Q/Q Earnings Growth (-15.00%)

Past

45/100

Ref Historical trends

Positives

Historically strong ROE and ROA
Consistent profitability over the long term

Watchpoints

Poor 1Y (-22.6%) and 3Y (-24.7%) price performance
Recent trend of missing earnings estimates

Health

70/100

Ref Altman Z-Score, Piotroski F-Score

Positives

Extremely low Debt/Equity (0.15)
Stable Piotroski F-Score (4/9)

Watchpoints

Quick Ratio below 1.0 (0.90)
Piotroski score is only 'Stable', not 'Strong'

Dividend

40/100

Ref Yield, Payout

Positives

Very low payout ratio (12%) ensures safety

Watchpoints

Negligible dividend yield (0.60%)

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$421.11

Analyst Target

$443.0

Upside/Downside

+5.2%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for CHE and closest competitors.

Updated 2026-04-24

Company	5Y	3Y	1Y	6M	1M	1W
CHE Chemed Corporation Primary	-8.1%	-24.7%	-22.6%	-3.3%	+12.6%	+9.5%
MIRM Mirum Pharmaceuticals, Inc. Peer	+417.6%	+286.1%	+143.7%	+33.7%	+6.4%	+0.3%
TGTX TG Therapeutics, Inc. Peer	-9.2%	+66.9%	-0.0%	+5.2%	+22.9%	+9.4%
PTCT PTC Therapeutics, Inc. Peer	+52.4%	+36.8%	+52.8%	+9.8%	+8.1%	+5.4%
CAI Caris Life Sciences, Inc. Peer	-33.0%	-33.0%	-33.0%	-40.6%	-1.3%	+4.9%

CHE

Chemed Corporation

Primary

-8.1%

-24.7%

-22.6%

-3.3%

+12.6%

+9.5%

MIR

Mirum Pharmaceuticals, Inc.

Peer

+417.6%

+286.1%

+143.7%

+33.7%

+6.4%

+0.3%

TGT

TG Therapeutics, Inc.

Peer

-9.2%

+66.9%

-0.0%

+5.2%

+22.9%

+9.4%

PTC

PTC Therapeutics, Inc.

Peer

+52.4%

+36.8%

+52.8%

+9.8%

+8.1%

+5.4%

CAI

Caris Life Sciences, Inc.

Peer

-33.0%

-40.6%

-1.3%

+4.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

22.99

15.75

1.62

5.9

2.23

2.11

13.21

$5.65B

Profitability

Profit margins and return metrics

Profit Margin 10.48%

Operating Margin 16.62%

Gross Margin 32.54%

ROE 25.28%

ROA 13.4%

Growth

Revenue and earnings growth rates

Revenue Growth -0.1%

Earnings Growth -9.1%

Q/Q Revenue Growth -0.1%

Q/Q Earnings Growth -15.0%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.15

Low debt

Current Ratio

1.05

Good

Quick Ratio

0.9

Poor

Cash/Share

$5.41

Quarterly Earnings History

EPS performance vs analyst estimates

2026-07-28

$N/A

2026-04-23

$5.65

+6.5% surprise

2026-02-25

$6.42

-8.7% surprise

2025-10-28

$5.27

-1.8% surprise

Healthcare Sector Comparison

Comparing CHE against 537 companies in the Healthcare sector (28 bullish, 159 neutral, 350 bearish)

P/E Ratio

22.99

This Stock

80.17

Sector Avg

-71.3% (Discount)

Return on Equity (ROE)

25.28%

This Stock

-91.87%

Sector Avg

-127.5% (Below Avg)

Profit Margin

10.48%

This Stock

-16.49%

Sector Avg

-163.6% (Weaker)

Debt to Equity

0.15

This Stock

2.73

Sector Avg

-94.6% (Less Debt)

Revenue Growth

-0.1%

This Stock

129.42%

Sector Avg

-100.1% (Slower)

Current Ratio

1.05

This Stock

4.57

Sector Avg

-76.9% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
CHE Chemed Corporation	BEARISH	$5.65B	22.99	25.3%	10.5%	$421.11
MIRM Mirum Pharmaceuticals, Inc.	BEARISH	$5.82B	-	-8.6%	-4.5%	$96.49	Compare
TGTX TG Therapeutics, Inc.	NEUTRAL	$5.9B	13.34	102.8%	72.6%	$36.96	Compare
PTCT PTC Therapeutics, Inc.	NEUTRAL	$6.0B	8.44	-%	39.4%	$72.43	Compare
CAI Caris Life Sciences, Inc.	NEUTRAL	$5.3B	-	-45.4%	-8.4%	$18.75	Compare

CHE Chemed Corporation

BEARISH

Mkt Cap

$5.6B

P/E

23.0

ROE

25.3%

Price

$421.11

Compare with CHE

TGTX TG Therapeutics, Inc.

Compare with CHE

PTCT PTC Therapeutics, Inc.

Compare with CHE

Compare with CHE

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-03-27	MCNAMARA KEVIN J	Chief Executive Officer	Sale	1,500	$554,055
2026-03-12	MCNAMARA KEVIN J	Chief Executive Officer	Sale	2,000	$806,360
2026-02-13	MCNAMARA KEVIN J	Chief Executive Officer	Option Exercise	2,714	$1,274,386
2026-02-13	WITZEMAN MICHAEL D.	Chief Financial Officer	Option Exercise	413	$193,928
2026-02-13	JUDKINS BRIAN C	Officer	Option Exercise	351	$164,816
2026-02-13	WHERLEY JOEL L	Officer	Stock Award	273	-
2026-02-13	LEE SPENCER S	Officer	Option Exercise	499	$234,310
2025-12-26	LINDELL ANDREA R	Director	Gift	463	-
2025-11-24	MCNAMARA KEVIN J	Chief Executive Officer	Sale	2,000	$875,100
2025-11-19	LEE SPENCER S	Officer	Gift	60	-

MCNAMARA KEVIN J

Chief Executive Officer

Sell

2026-03-27

1,500 shares · $554,055

MCNAMARA KEVIN J

Chief Executive Officer

Sell

2026-03-12

2,000 shares · $806,360

MCNAMARA KEVIN J

Chief Executive Officer

Option Exercise

2026-02-13

2,714 shares · $1,274,386

WITZEMAN MICHAEL D.

Chief Financial Officer

Option Exercise

2026-02-13

413 shares · $193,928

JUDKINS BRIAN C

Officer

Option Exercise

2026-02-13

351 shares · $164,816

WHERLEY JOEL L

Officer

Stock Award

2026-02-13

273 shares

LEE SPENCER S

Officer

Option Exercise

2026-02-13

499 shares · $234,310

LINDELL ANDREA R

Director

Gift

2025-12-26

463 shares

MCNAMARA KEVIN J

Chief Executive Officer

Sell

2025-11-24

2,000 shares · $875,100

LEE SPENCER S

Officer

Gift

2025-11-19

60 shares

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K

2026-04-23

Chemours Company reported its first quarter 2026 financial results.

8-K

2026-04-13

Chemours Company likely filed this 8-K to announce its first quarter 2026 financial results.

DEF 14A

2026-04-06

CHE filed a definitive proxy statement (DEF 14A) on April 6, 2026, providing shareholders with necessary information and voting materials for the upcoming annual meeting.

10-K

FORM 10-K

2026-02-27

CHE submitted its annual 10-K filing on February 27, 2026, which includes comprehensive disclosures regarding its business operations and financial condition. The report contains dedicated sections for risk factors and quantitative market risk disclosures, although specific financial metrics were not provided in the available excerpts.

8-K

2026-02-25

The Chemours Company filed an 8-K to report its fourth-quarter and full-year financial results for 2025.

10-Q

2025-10-31

CHE filed its quarterly 10-Q report on October 31, 2025. While specific financial highlights were not provided in the excerpt, the filing includes a dedicated section detailing the company's risk factors.

8-K

2025-10-28

Chemours Company likely filed this 8-K to announce its third-quarter financial results.

10-Q

2025-07-31

CHE filed its quarterly 10-Q report on July 31, 2025. While the filing includes a section dedicated to risk factors, no specific financial highlights or detailed risk descriptions were provided in the available excerpt.

8-K

FORM 8-K

2025-07-29

The Chemours Company likely filed this 8-K to announce its second-quarter financial results.

8-K

2025-06-27

8-K

2025-05-20

10-Q

2025-04-28

8-K

2025-04-23

DEF 14A

2025-04-07

10-K

2025-02-28

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

BUY

4 analysts

RBC Capital

2026-02-27

down

Outperform Sector Perform

Oppenheimer

2026-02-27

Maintains

Outperform Outperform

Jefferies

2026-01-22

down

Buy Hold

RBC Capital

2025-11-10

Maintains

Outperform Outperform

Past News Coverage

Recent headlines mentioning CHE from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

CHE

CHE Chemed Corporation - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!